sry retatrutide Retatrutide: The New Triple-Agonist Weight Loss Treatment Retatrutide Peptide 20mg (RUO) |

Expert Opinion on Drug Safety , 18

In a Phase 2 obesity trial of retatrutide published in the New England Journal of Medicine in 2023, nausea, diarrhea, vomiting and constipation were cited as the most common adverse events, with higher doses associated with more severe problems

By combining both hormones, these medications tend to produce stronger results than GLP-1 alone

doctors are leaving the specialty, national study finds1:539 hours ago Health Matters: Rexulti class-action lawsuit deadline approaching2:1914 hours ago Florida man sues OpenAI after ChatGPT medical advice put his life at risk2:022 days ago Heat and air quality warnings remain in place in the Okanagan2:014 days ago CIHI report finds core online health records not accessible to all1:275 days ago Health Matters: New graphic cigarette warning labels4:055 days ago Health Matters: Canadian Blood Services faces donation shortage2:105 days ago Cyclospora outbreak in the U.S